Delivery Order SPE2DB22D1002-SPE2DB25FLGH9
- Not listed
- The Defense Logistics Agency awarded a $13,630.99 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $10,295.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Dupixent 300 mg/2 mL pen auto-injectors. The contract, which is classified as a child order under a larger vehicle, carries an ultimate completion date of September 17, 2025, and represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $56,394.80 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's distribution...
- The Defense Logistics Agency awarded a delivery order valued at $117,847.83 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of September 2, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication commonly prescribed for conditions...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $36,620.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections (2 ml) with an ultimate completion date of May 23, 2025. This contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively granted with no set-aside designation and will be...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $35,600.20 on August 29, 2025, for Dupixent 300 mg/2 mL pen auto-injectors. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by September 2, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $19,398.30 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This is a firm fixed price, non-set-aside contract with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase under AmerisourceBergen's larger contract vehicle with...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLGH9Delivery Order
The Defense Logistics Agency awarded a $31,503.39 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed price contract is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order represents a task under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at approximately $1 billion through December 2026. The parent IDC, designated SPE2DX, serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis, and this delivery fulfills critical pharmaceutical supply needs for Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.5k | 8/14/25 |